Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 2.7% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was down 2.7% during trading on Tuesday . The company traded as low as $34.76 and last traded at $35.03. Approximately 304,832 shares changed hands during trading, a decline of 51% from the average daily volume of 621,542 shares. The stock had previously closed at $36.00.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on DNTH shares. Guggenheim raised their target price on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Robert W. Baird lifted their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, September 9th. William Blair began coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an “outperform” rating on the stock. Stifel Nicolaus lifted their price objective on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, September 8th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.88.

Dianthus Therapeutics Stock Down 2.7%

The business’s fifty day moving average is $31.73 and its two-hundred day moving average is $23.56. The stock has a market capitalization of $1.13 billion, a PE ratio of -10.78 and a beta of 1.58.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.87 million. Sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 16.56% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. RA Capital Management L.P. grew its holdings in shares of Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock valued at $52,003,000 after purchasing an additional 1,000,333 shares in the last quarter. Moody Aldrich Partners LLC purchased a new position in shares of Dianthus Therapeutics in the first quarter valued at $1,349,000. Walleye Capital LLC boosted its stake in Dianthus Therapeutics by 29.0% during the first quarter. Walleye Capital LLC now owns 106,931 shares of the company’s stock worth $1,940,000 after buying an additional 24,041 shares during the period. Vestal Point Capital LP boosted its stake in Dianthus Therapeutics by 58.1% during the first quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock worth $30,839,000 after buying an additional 625,069 shares during the period. Finally, Nuveen LLC purchased a new position in Dianthus Therapeutics during the first quarter worth $1,168,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.